Back to Search
GURU SONPAVDE, MD
MD
Medical Oncology Physician
NPI: 1083655716IndividualAccepts Medicare
Specialties, Licenses & Credentials
Medical Oncology PhysicianPrimary
Internal Medicine — Medical Oncology
Code: 207RX0202X
271600(MA)ME154902(FL)
CMS Specialties
PrimaryMEDICAL ONCOLOGY
Education
OTHER
Class of 1990
Research & Publications (20)
Target-specific randomized discontinuation trial design: a novel approach in molecular therapeutics.
PMID 19262991·Invest New Drugs·2010
8-other
Sunitinib malate for metastatic castration-resistant prostate cancer following docetaxel-based chemotherapy.
PMID 19633050·Ann Oncol·2010
3-trial
Enzastaurin shows preclinical antitumor activity against human transitional cell carcinoma and enhances the activity of gemcitabine.
PMID 19509273·Mol Cancer Ther·2009
7-preclinical
Residual pathological stage at radical cystectomy significantly impacts outcomes for initial T2N0 bladder cancer.
PMID 19524971·J Urol·2009
8-other
Ketoconazole retains activity in patients with docetaxel-refractory prostate cancer.
PMID 19403937·Ann Oncol·2009
8-other
Quality of pathologic response and surgery correlate with survival for patients with completely resected bladder cancer after neoadjuvant chemotherapy.
PMID 19517476·Cancer·2009
8-other
Treatment of metastatic urothelial cancer: opportunities for drug discovery and development.
PMID 19035904·BJU Int·2008
6-review
Neoadjuvant chemotherapy preceding cystectomy for bladder cancer.
PMID 18627327·Expert Opin Pharmacother·2008
6-review
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
Via practice · 2 locations total
- Address
- 2501 N ORANGE AVE STE 689
ORLANDO, FL 32804 - Phone
- (407) 303-2024
Quick Facts
- NPI
- 1083655716
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 4
- Locations
- 2
- Years in Practice
- 36
- Publications
- 20
Are you this provider?
Claim Your Profile